TBPH Q3 2025 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+18.5% YoY

Gross Profit

$12M59.4% margin

Operating Income

-$6M-32.3% margin

Net Income

$4M18.1% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-23.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$415M

Total Liabilities

$183M

Stockholders' Equity

$233M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$17M	+18.5%
Gross Profit	$12M	$8M	+56.3%
Operating Income	-$6M	-$11M	+40.4%
Net Income	$4M	-$13M	+128.5%

Revenue Segments

Collaborative Arrangement Revenue

$20M73%

License

$8M27%